` ABP (ABPRO Holdings Inc) vs S&P 500 Comparison - Alpha Spread

ABP
vs
S&P 500

Over the past 12 months, ABP has underperformed S&P 500, delivering a return of -92% compared to the S&P 500's +14% growth.

Stocks Performance
ABP vs S&P 500

Loading
ABP
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ABP vs S&P 500

Loading
ABP
S&P 500
Difference
www.alphaspread.com

Performance By Year
ABP vs S&P 500

Loading
ABP
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
ABPRO Holdings Inc vs Peers

S&P 500
ABP
MTSR
GRAL
347850
ONESOURCE
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

ABPRO Holdings Inc
Glance View

Market Cap
13.5m USD
Industry
N/A

ABPRO Holdings Inc is a US-based company operating in industry. The company is headquartered in New York City, New York. The company went IPO on 2022-01-14. Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The firm is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.

ABP Intrinsic Value
0.79 USD
Overvaluation 84%
Intrinsic Value
Price
Back to Top